Blog
ACM Research (ACMR) Is Considered a Good Investment by Brokers: Is That True?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts
Brokers Suggest Investing in Nu (NU): Read This Before Placing a Bet
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm
Circle Internet Group, Inc. (CRCL) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
For the quarter ended September 2025, Circle Internet Group, Inc. (CRCL) reported revenue of $739.76 million, representing no change compared to the same period last year. EPS came in at $0.64
Brokers Suggest Investing in e.l.f. Beauty (ELF): Read This Before Placing a Bet
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm
European Wax Center (EWCZ) Reports Q3 Earnings: What Key Metrics Have to Say
For the quarter ended September 2025, European Wax Center, Inc. (EWCZ) reported revenue of $54.19 million, down 2.3% over the same period last year. EPS came in at $0.25, compared to $0.12 in the
Adma Biologics (ADMA) Crossed Above the 50-Day Moving Average: What That Means for Investors
Adma Biologics (ADMA) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ADMA broke through the 50-day moving average, which suggests
HudBay Minerals (HBM) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
HudBay Minerals (HBM) reported $346.8 million in revenue for the quarter ended September 2025, representing a year-over-year decline of 28.6%. EPS of $0.03 for the same period compares to $0.13 a
GlobalFoundries (GFS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
For the quarter ended September 2025, GlobalFoundries Inc. (GFS) reported revenue of $1.69 billion, down 2.9% over the same period last year. EPS came in at $0.41, compared to $0.41 in the year-ago
Is Intuit (INTU) a Buy as Wall Street Analysts Look Optimistic?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side)
McGraw Hill, Inc. (MH) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
For the quarter ended September 2025, McGraw Hill, Inc. (MH) reported revenue of $669.19 million, representing no change compared to the same period last year. EPS came in at $1.40, compared to $0
PagSeguro Digital Ltd. (PAGS) Recently Broke Out Above the 50-Day Moving Average
PagSeguro Digital Ltd. (PAGS) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, PAGS broke through the 50-day moving average, which
Boston Scientific (BSX) Crossed Above the 200-Day Moving Average: What That Means for Investors
Boston Scientific (BSX) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, BSX crossed above the 200-day moving average
Victory Capital's October AUM Rises Sequentially to $313B on Equity Gains
Victory Capital Holdings, Inc. VCTR reported assets under management (AUM) of $313 billion for October 2025. This reflected an increase of nearly 1% from September 2025.
By asset class, VCTR’s U.S
HIVE Digital to Report Q2 Earnings: What's in Store for the Stock?
HIVE Digital Technologies HIVE is set to report second-quarter fiscal 2026 results on Nov. 14, 2025.The Zacks Consensus Estimate for second-quarter fiscal 2026 revenues is pegged at $80.96 million
TON Strategy Company (TONX) Reports Q3 Loss, Beats Revenue Estimates
TON Strategy Company (TONX) came out with a quarterly loss of $1 per share versus the Zacks Consensus Estimate of a loss of $1.9. This compares to a loss of $3.97 per share a year ago. These figures
INPLAY OIL CP (IPOOF) Reports Q3 Loss, Misses Revenue Estimates
INPLAY OIL CP (IPOOF) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of $0.07. This compares to break-even earnings per share a year ago. These figures are
Boot Barn Raises FY26 Sales Target to $2.24B: Still Room to Run?
Boot Barn Holdings Inc. BOOT has upped its sales forecast for fiscal 2026. It now expects total sales between $2,197 million and $2,235 million, which suggests year-over-year growth of 15% to 17%
UNIVERSAL INSURANCE HOLDINGS INC (UVE) Hits Fresh High: Is There Still Room to Run?
Have you been paying attention to shares of Universal Insurance Holdings (UVE)? Shares have been on the move with the stock up 17% over the past month. The stock hit a new 52-week high of $35.32 in
LiveOne (LVO) Reports Q2 Loss, Beats Revenue Estimates
LiveOne (LVO) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to a loss of $0.2 per share a year ago. These figures are
Crexendo Inc. (CXDO) Soars to 52-Week High, Time to Cash Out?
A strong stock as of late has been Crexendo (CXDO). Shares have been marching higher, with the stock up 24.1% over the past month. The stock hit a new 52-week high of $7.65 in the previous session
Black Diamond Therapeutics, Inc. (BDTX) Hits Fresh High: Is There Still Room to Run?
Shares of Black Diamond (BDTX) have been strong performers lately, with the stock up 22.9% over the past month. The stock hit a new 52-week high of $4.65 in the previous session. Black Diamond has
Countdown to Aramark (ARMK) Q4 Earnings: Wall Street Forecasts for Key Metrics
Wall Street analysts expect Aramark (ARMK) to post quarterly earnings of $0.65 per share in its upcoming report, which indicates a year-over-year increase of 20.4%. Revenues are expected to be
Lucid Diagnostics Inc. (LUCD) Reports Q3 Loss, Lags Revenue Estimates
Lucid Diagnostics Inc. (LUCD) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.2 per share a year ago. These
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income
Here's a revealing data point: older Americans are scared more of outliving wealth than of death itself.
And older Americans have legitimate reasons for this worry, even if they have dutifully saved
Astria Therapeutics, Inc. (ATXS) Reports Q3 Loss, Misses Revenue Estimates
Astria Therapeutics, Inc. (ATXS) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to a loss of $0.42 per share a year ago


